Drug Profile

QR 1011

Alternative Names: QR-1011

Latest Information Update: 28 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ProQR Therapeutics
Class Antisense oligonucleotides; Eye disorder therapies
Mechanism of Action ATP binding cassette transporter subfamily A member 4 expression stimulants; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

31 Dec 2022 ProQR Therapeutics has patent protection for chemically modified single-stranded rna-editing oligonucleotides in Europe, Japan, New Zealand, South Korea, South Africa and the US
31 Dec 2022 ProQR Therapeutics has patents pending for chemically modified single-stranded rna-editing oligonucleotides in Australia, Canada, China, India, and the US (continuation applications)
26 Apr 2022 Preclinical trials in Stargardt disease in Netherlands (Intravitreous) before April 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com